Immediate Infusion Reaction to Intravenous Ustekinumab in Three Crohn's Disease Patients: A Case Report and Review of the Literature.

Published on Jan 13, 2021in Journal of Crohn's and Colitis8.658
· DOI :10.1093/ECCO-JCC/JJAA115
Pepijn W. A. Thomas1
Estimated H-index: 1
(Radboud University Nijmegen),
Gerben Ferwerda30
Estimated H-index: 30
+ 1 AuthorsFrank Hoentjen16
Estimated H-index: 16
(Radboud University Nijmegen)
Sources
Abstract
Recently, ustekinumab has been approved for the treatment of Crohn's disease and ulcerative colitis. Treatment is started with an intravenous induction dose, followed by a subcutaneous dosage. We present three patients with therapy-refractory Crohn's disease, who experienced an immediate infusion reaction to intravenous administration of ustekinumab. In two of these patients a subsequent reaction to subcutaneous injections occurred. Clinical features and pathophysiology are discussed.
📖 Papers frequently viewed together
2018
9 Authors (W J Sandborn, ..., S. B. Hanauer)
1 Citations
2018
1 Citations
References14
Newest
#1João Gonçalves (University of Lisbon)H-Index: 34
#2Gihyun Myung (Samsung)H-Index: 2
Last. Jeehoon Ghil (Samsung)H-Index: 9
view all 5 authors...
Background:The primary objective of this study was to analyze the cross-reactivity of antidrug antibodies to reference adalimumab (ADL) and SB5 (adalimumab biosimilar) in patients with inflammatory...
6 CitationsSource
2 CitationsSource
#1Severine Vermeire (Katholieke Universiteit Leuven)H-Index: 146
#2Ann Gils (Katholieke Universiteit Leuven)H-Index: 57
Last. Amy Marren (Pfizer)H-Index: 8
view all 5 authors...
Crohn’s disease and ulcerative colitis are chronic inflammatory disorders of the gastrointestinal tract. Treatment options include biologic therapies; however, a proportion of patients lose response to biologics, partly due to the formation of anti-drug antibodies (ADAbs). Concomitant immunosuppressive agents reduce the development of ADAbs. This review article aims to assess the immunogenicity of biologic therapies and their clinical implications. A comprehensive literature search was conducted...
98 CitationsSource
#1Giuseppe MurdacaH-Index: 31
#2Francesca SpanòH-Index: 14
Last. Francesco PuppoH-Index: 45
view all 7 authors...
Introduction: TNF-α inhibitors have demonstrated efficacy both as monotherapy and in combination with disease-modifying antirheumatic drugs (DMARDs) in the treatment of chronic inflammatory immune-mediated diseases such as rheumatoid arthritis, Crohn’s disease, ankylosing spondylitis, psoriasis and/or psoriatic arthritis, and may be administered off-label to treat disseminated granuloma annulare systemic lupus erythematosus and systemic sclerosis. There are several TNF-α inhibitors available for...
52 CitationsSource
#1Arne HomannH-Index: 2
#1Arne HomannH-Index: 1
Last. Uta JappeH-Index: 37
view all 5 authors...
Background Autoimmune diseases like rheumatoid arthritis and inflammatory bowel disease are treated with TNF-alpha-blocking antibodies such as infliximab and adalimumab. A common side effect of therapeutic antibodies is the induction of anti-drug antibodies, which may reduce therapeutic efficacy.
15 CitationsSource
#1Lev Lichtenstein (TAU: Tel Aviv University)H-Index: 5
#2Yulia Ron (Tel Aviv Sourasky Medical Center)H-Index: 15
Last. Batia Weiss (TAU: Tel Aviv University)H-Index: 25
view all 10 authors...
Objective: Administration of infliximab is associated with a well-recognised risk of infusion reactions. Lack of a mechanism-based rationale for their prevention, and absence of adequate and well-controlled studies, has led to the use of diverse empirical administration protocols. The aim of this study is to perform a systematic review of the evidence behind the strategies for preventing infusion reactions to infliximab, and for controlling the reactions once they occur. Methods: We conducted ex...
100 CitationsSource
#1Paul A. J. Russo (Royal Adelaide Hospital)H-Index: 4
#2Tatjana BanovicH-Index: 14
Last. William B Smith (Royal Adelaide Hospital)H-Index: 21
view all 5 authors...
We describe a patient with EDTA allergy, identified through investigation of reactions to local anaesthetic (LA) and radiocontrast medium (RCM). A 57-year-old man with a history of seasonal allergic rhinitis received a subcutaneous injection of approximately 2 mL of lignocaine 20 mg/mL, with adrenaline tartrate 12.5 mcg/mL (Lignospan Special [LS], Specialites Septodont, Emu Plains, New South Wales, Australia) (which also contains potassium metabisulfite and disodium EDTA [dsEDTA] 0.25 mg/mL) bef...
12 CitationsSource
#1William J. Sandborn (UCSD: University of California, San Diego)H-Index: 182
#2Brian G. Feagan (UWO: University of Western Ontario)H-Index: 115
Last. Asit Parikh (Millennium Pharmaceuticals)H-Index: 18
view all 17 authors...
BackgroundUstekinumab, a monoclonal antibody to the p40 subunit of interleukin-12 and interleukin-23, was evaluated as an intravenous induction therapy in two populations with moderately to severely active Crohn’s disease. Ustekinumab was also evaluated as subcutaneous maintenance therapy. MethodsWe randomly assigned patients to receive a single intravenous dose of ustekinumab (either 130 mg or approximately 6 mg per kilogram of body weight) or placebo in two induction trials. The UNITI-1 trial ...
1,581 CitationsSource
#1Brian G. Feagan (UWO: University of Western Ontario)H-Index: 115
#2Paul Rutgeerts (Katholieke Universiteit Leuven)H-Index: 167
Last. Asit Parikh (Takeda Pharmaceutical Company)H-Index: 18
view all 16 authors...
We conducted two integrated randomized, double-blind, placebo-controlled trials of vedolizumab in patients with active disease. In the trial of induction therapy, 374 pa tients (cohort 1) received vedolizumab (at a dose of 300 mg) or placebo intravenously at weeks 0 and 2, and 521 patients (cohort 2) received open-label vedolizumab at weeks 0 and 2, with disease evaluation at week 6. In the trial of maintenance therapy, patients in either cohort who had a response to vedolizumab at week 6 were r...
1,472 CitationsSource
#1Stephen J. Galli (Stanford University)H-Index: 130
#2Mindy Tsai (Stanford University)H-Index: 63
Last. Mindy Tsai (Stanford University)H-Index: 28
view all 2 authors...
Both mast cells and IgE play crucial parts during the initiation and amplification of the allergic response during asthma, as well as during the tissue remodeling that occurs at the chronic stage. This review discusses how these two players can affect the development of asthma through independent and interdependent functions and the therapeutic implications for treating the clinical symptoms derived from allergic disease.
982 CitationsSource
Cited By1
Newest
#1Sheena Crosby (Mayo Clinic)H-Index: 1
#2Michael J Schuh (Mayo Clinic)H-Index: 3
Last. Francis A Farraye (Mayo Clinic)H-Index: 6
view all 3 authors...
Source